Fetching results...
0 items found

P079: Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

Stenzl A.1, Saad F.2, De Bono J.S.3, Higano C.S.4, Barthelemy P.5, Dorff T.6, Mehra N.7, Scagliotti G.V.8, Machiels J-P.9, Renard V.10, Maruzzo M.11, Gurney H.12, Stirling A.13, Cynthia G. H.14, Bhattacharyya H.15, Arondekar B.16, Niyazov A.17, Fizazi K.18
1University of Tübingen Medical School, Department of Urology, Tübingen, Germany, 2Institut du Cancer de Montreal, Division of Urology, Montreal, Canada, 3The Institute of Cancer Research and Royal Marsden Hospital, Division of Clinical Studies, London, United Kingdom, 4University of British Columbia, Dept. of Urologic Science, Vancouver, Canada, 5Institut de Cancérologie Strasbourg Europe, Medical Oncology Unit, Strasbourg, France, 6City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology & Therapeutics Research, Duarte, United States of America, 7Radboud University Medical Center, Dept. of Medical Oncology, Nijmegen, The Netherlands, 8University of Turin, San Luigi Gonzaga Hospital, Dept. of Oncology, Orbassano, Italy, 9Cliniques Universitaires Saint-Luc, Dept. of Medical Oncology, Brussels, Belgium, 10AZ Sint-Lucas, Dept. of Medical Oncology, Ghent, Belgium, 11Istituto Oncologico Veneto IOV – IRCCS, Dept. of Oncology, Padova, Italy, 12Westmead Hospital, Dept. of Medical Oncology, Westmead, Australia, 13ICON Cancer Centre, Medical Oncology, Brisbane, Australia, 14Pfizer Inc, Dept. of Oncology, Collegeville, United States of America, 15Pfizer Inc, Dept. of Biostatistics and Data Management, New York, United States of America, 16Pfizer Inc, Dept. of Patient and Health Impact, Collegeville, United States of America, 17Pfizer Inc, Dept. of Patient and Health Impact, New York, United States of America, 18Institut Gustave Roussy, University of Paris Saclay, Dept. of Oncology, Villejuif, France
13th European Multidisciplinary Congress on Urological Cancers
Date – Time - Location
25 November 2021, 00:00 - 00:00, PDF
EMUC e-posters - e-posters
Prostate Cancer, Metastatic - Follow up, Quality of life / Patient reported outcomes

Introduction & Objectives

In TALAPRO-1, TALA showed antitumor activity and a manageable toxicity profile in men with mCRPC and DNA damage repair alteration in genes either directly or indirectly involved in homologous recombination repair. A secondary study objective was to evaluate patient (pt)-reported pain as measured by the Brief Pain Inventory Short Form (BPI-SF).

Materials & Methods

TALAPRO-1, a single-arm, phase 2 study, included men with mCRPC who had received 1-2 taxane-based regimens for advanced prostate cancer and whose mCRPC progressed on ≥1 novel hormonal agents (abiraterone and/or enzalutamide). Pain in pts treated with TALA was assessed via BPI-SF at baseline, every 2 weeks (wks) up to wk 9, every 4 wks through wk 25, and every 12 wks thereafter until radiographic disease progression. Longitudinal mixed-effects model analyses estimated overall change from baseline scores. Results were stratified by baseline pain status (asymptomatic/mild [BPI score 0–4], and moderate/severe [BPI score 5–10]) and reported for all pts and the BRCA1/2 and non-BRCA1/2 subsets.


A total of 83 pts were included in this analysis; 45 had asymptomatic/mild pain (BRCA1/2, n=29; non-BRCA1/2, n=16) and 38 had moderate/severe pain (BRCA1/2, n=22; non-BRCA1/2, n=16). In pts with baseline asymptomatic/mild pain, no change in worst pain, pain severity, and pain interference were observed in all patients (including the BRCA1/2 and the non-BRCA1/2 subset; Figure 1A). In pts with moderate/severe baseline pain, an improvement in pain was observed (except for pain interference in the non-BRCA1/2 subset; Figure 1B).


In this heavily pre-treated population from TALAPRO-1, TALA treatment was associated with no change in measures of pain burden in all groups of pts with asymptomatic/mild baseline pain status. In pts with moderate/severe baseline pain status, TALA treatment was associated with improved measures of pain burden, except pain interference in the non-BRCA1/2 subset which did not change. These findings, combined with the antitumor activity and tolerability of TALA, suggest a favorable benefit of TALA in this pt population.
Funding: Pfizer Inc (NCT03148795)

Fetching poster...
  • © 2022 European Association of Urology
  • Disclaimer